| Document |
Document Title |
|
WO/2001/066514A1 |
The invention relates to a method for separating by distillation a portion or the entirety of an azeptine derivative (III), which is selected from the group consisting of aminohexylidene imine, tetrahydroazepine, hexylhexahydroazepine an...
|
|
WO/2001/064624A1 |
The invention relates to a method for reducing the quantity of an unsaturated imine (III) contained in a mixture (II) containing an imine (III) and an amine (I), characterised in that the mixture (II) is treated with an oxidation agent (...
|
|
WO/2001/056992A2 |
The invention relates to new processes for the preparation of the pharmaceutical oxcarbazepine as well as novel intermediates (I), (V), (VI), (VII), (IX) prepared by or used for said processes, and the preparation of said intermediates. ...
|
|
WO/2001/055118A1 |
Benzene-fused heterocycle derivatives of the general formula (I); and nontoxic salts thereof (wherein each symbol is as defined in the description). The compounds of the general formula (I) exhibit inhibitory activities against cysteine ...
|
|
WO/2001/051474A2 |
One aspect of the present invention relates to polypharmacophoric compounds. In certain embodiments, the polypharmacophore compounds comprise individual pharmacophore units selected from the group consisting of D-1 agonists, D-2 agonists...
|
|
WO/2001/051479A2 |
The present invention provides a compound of the formula (I) and pharmaceutically acceptable salts having useful antiviral activity against viruses of the herpes family. In said formula, X = O, (CH¿2?)¿m?, S, SO, SO¿2?, NH, NR¿8? or ...
|
|
WO/2001/049665A2 |
The invention relates to a method for purifying lactames, especially lactames obtained by cyclization hydrolysis of an aminoalkylnitrile, and more particularly, to the purification of $g(e)-caprolactame obtained by cyclization hydrolysis...
|
|
WO/2001/046141A1 |
The invention relates to a method for the production of N-alkenyl amides, by reaction of the corresponding NH-amide, with acetylenes, in the liquid phase, in the presence of basic alkali metal compounds and a co-catalyst. Said co-catalys...
|
|
WO/2001/046139A1 |
The invention relates to a method for producing N-alkenyl amides, by reacting the appropriate NH-amides with acetylenes in the liquid phase, in the presence of basic alkali metal compounds and a co-catalyst. According to said method, com...
|
|
WO/2001/042208A1 |
Therapeutic or preventive agents for CCR5-related diseases such as AIDS, rheumatoid arthritis and nephritis, containing as the active ingredient cycloamine derivatives of general formula (I), pharmaceutically acceptable adducts of the sa...
|
|
WO1999064041A9 |
Disclosed are novel multi-binding compounds (agents) which bind to NMDA receptors. The compounds of this invention comprise a plurality of ligands each of which can bind to such receptors, thereby modulating the biological processes and/...
|
|
WO/2001/035964A1 |
This invention relates to substituted 1-benzazepines and derivatives thereof useful as antibacterial agents, to compositions, including pharmaceutical compositions, comprising such compounds, to processes for making these compounds and t...
|
|
WO/2001/034571A1 |
The present invention relates $g(b)-aminoacid containing compounds of formula (I) which inhibit $g(b)-amyloid peptide release and/or its synthesis and are useful in treating Alzheimer's disease and cognition enhancement.
|
|
WO/2001/029005A1 |
Compounds according to general formula (1), and pharmaceutically acceptable salts thereof, wherein V is a covalent bond or NH, X is selected from CH¿2?, O and N-alkyl, Z is either S or -CH=CH-, R?1¿ and R?2¿ are independently selected...
|
|
WO/2001/025212A2 |
The invention relates to compounds of general formula (I), wherein the radicals R independently represent a hydroxy group, a hydrogen atom, a halogen atom, a pseudohalogen, a substituent, an optionally substituted alkyl radical, alkenyl ...
|
|
WO/2001/023497A1 |
An organic electroluminescent element which has a high color purity, high luminescent efficiency, and long life and emits a red color; and a novel compound. The organic electroluminescent element comprises at least one pair of electrodes...
|
|
WO/2001/023357A2 |
The invention comprises novel compounds of formula E-B-(Alk)¿p?-Q-(Alk)¿q?-A-G wherein G is a radical of formula (I), (II) or (III) that are effective in the prophylaxis and treatment of diseases, such as integrin receptors mediated di...
|
|
WO/2001/021305A1 |
The present invention relates to porous catalysts comprising layered silicate and metal oxides, and a method of preparing $g(e)-caprolactam from cyclohexanone oxime using the catalyst. This new catalyst can resolve the environmental and ...
|
|
WO/2001/019797A2 |
This invention relates to novel lactams having formula (I) to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the pr...
|
|
WO/2001/017947A1 |
A process for preparing 2,3-dihydroazepine compounds of general formula (1) or salts thereof inexpensively and simply, characterized by reacting a compound of general formula (2) or a salt thereof with a compound of general formula (3) o...
|
|
WO/2001/017971A1 |
A process for preparing 2,3-dihydroazepine derivatives of general formula (II) or salts thereof inexpensively and simply, characterized by subjecting compounds of general formula (I) or salts thereof to ring-closing reaction in the prese...
|
|
WO/2001/016110A1 |
Formulation components such as bleach boosting compounds selected from the group consisting of bleach boosters comprising quaternary imine cations, zwitterions, polyions having a net charge of from about +3 to about -3 and mixtures there...
|
|
WO/2001/014328A2 |
Compounds of Formula (I) are antagonists of VLA-4 and/or $g(a)4$g(b)7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical ...
|
|
WO/2001/012549A1 |
The invention relates to a process for treating a mixture, in particular a neutralized Beckmann rearrangement mixture, comprising i) an ammonium sulfate solution phase containing first organic impurities and ii) an aqueous lactam phase c...
|
|
WO/2001/010847A2 |
The invention relates to novel compounds of formula (I) which bind to integrin receptors, wherein G and L have the following meaning: L is a structural element of formula I¿L?, wherein T represents a COOH group or a radical that can be ...
|
|
WO/2001/005765A1 |
Compounds (I) R and R¿1? independently = H or C¿1?-C¿4? alkyl or together = (CH¿2?)¿2-6?, n=0 or 1, ...... is a single or a double bond, A=CO or CH¿2?, A¿1? represents a CO or CH¿2? or CH, each R¿3? independently = H or C¿1?-CÂ...
|
|
WO/2001/003699A1 |
The invention relates to the utilization of benzazepine-N-acetic acid derivatives which contain an oxogroup in addition to the nitrogen atom in the $g(a) position and which are substituted in the third position by a 1-(carboxyalkyl)-cycl...
|
|
WO/2001/002368A1 |
The present invention relates to N-heterocyclic derivatives for treating or preventing neuronal damage associated with neurological diseases. The invention also provides compositions comprising the compounds of the present invention and ...
|
|
WO/2001/002358A2 |
The present invention relates to cyclized amide derivatives of formula (I) for treating or preventing neuronal damage associated with neurological diseases. The invention also provides compositions comprising the compounds of the present...
|
|
WO/2000/077002A1 |
The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R?1¿, R?5¿, R?6a¿, R?6b¿, R?7¿, R?8¿, R?9¿, X, b, k, m, and n, and the d...
|
|
WO/2000/077010A2 |
The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R?1¿, R?5¿, R?6a¿, R?6b¿, R?7¿, R?8¿, R?9¿, X, b, k, m, and n, and the d...
|
|
WO/2000/076981A1 |
Disclosed are piperidinyl and piperazinyl substituted benzofused lactam compounds which are useful for the treatment and/or prevention of neuropsychological disorders including, but not limited to, schizophrenia, mania, dementia, depress...
|
|
WO/2000/077001A1 |
The present invention is directed to certain novel compounds represented by structural Formula (I): or pharmaceutically acceptable salt forms thereof, wherein R?1¿, R?5¿, R?6a¿, R?6b¿, R?7¿, R?8¿, R?9¿, X, b, k, m, and n, and the ...
|
|
WO/2000/076993A1 |
Compounds of general formula (I) or salts thereof, which exhibit CCR5 antagonism and exert preventive and therapeutic effects against HIV infections: wherein R?1¿ is a five- or six-membered aromatic ring which bears a substituent repres...
|
|
WO/2000/072801A2 |
The present invention relates to novel nonanoic acid derivatives, their synthesis, and their use as alphaV integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors...
|
|
WO/2000/071518A2 |
One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate rece...
|
|
WO/2000/069432A1 |
Remedies or preventives for diseases in association with chemokines such as MIP-1$g(a) and/or MCP-1. Namely, remedies or preventives for diseases in association with chemokines (rheumatoid arthritis, nephritis, etc.) which contain as the...
|
|
WO/2000/066561A1 |
Process for the preparation of caprolactam in which there is formed an ammonium sulphate solution from which ammonium sulphate crystals and a condensate are obtained in a crystallisation step, with the condensate being purified and retur...
|
|
WO/2000/063209A1 |
The present invention relates to compounds of general formula (I). The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PP...
|
|
WO/2000/057868A2 |
A pharmaceutical composition that inhibits or slows the growth of viruses in animals, particularly in mammals, is disclosed. This same composition can be used to treat viral infections, particularly HIV. The composition comprises from ab...
|
|
WO/2000/058294A1 |
Compounds of formula (I) are antibacterial agents wherein: R¿3? and R¿4?, taken together with the carbon atoms to which they are respectively attached, form an optionally substituted saturated carbocyclic or heterocyclic ring of 5 to 1...
|
|
WO/2000/055137A1 |
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective modulators for ER-$g(b) over ER-$g(a). Methods are disclo...
|
|
WO/2000/055138A1 |
The invention relates to a method of producing 10,11- dihydro- 10- oxo- 5H- dibenz(b,f)- azepine- 5- carboxamide on the basis of 5- chlorocarbonyl- 5H- dibenz(b,f)- azepine which is nitrated to give the corresponding nitro compound of fo...
|
|
WO/2000/054759A2 |
The invention provides compounds, compositions and methods for modulating the effects of LXR in a cell. The compounds and compositions are useful both as diagnostic indicators of LXR function and as pharmacologically active agents. The c...
|
|
WO/2000/049000A1 |
The invention provides 2,3,4,5-tetrahydro-1H-3-benzazepines of general formula (I) wherein: R?1¿ is hydrogen, halogen, C¿1?-C¿4? alkyl, or CF¿3?; R?2¿ is hydrogen, methyl, or lower alkenyl of 3-5 carbon atoms; R?3¿ and R?4¿ togeth...
|
|
WO/2000/048601A1 |
The invention relates to the use of benzazepine-N ethanoic acid derivatives, containing an oxo group bonded to the nitrogen atom in the $g(a)-position and which are substituted by a 1-(carboxy alkyl)-cyclopentyl-carbonyl amino radical in...
|
|
WO/2000/048974A1 |
The invention relates to a composition of vinyl compounds containing e) at least one polymerisable compound that is provided with at least one O-vinyl group or N-vinyl group and f) at least one ammonium salt of general formula (I) wherei...
|
|
WO/2000/048984A1 |
The invention relates to a process to separate linear 5-formylvalerate compound from a crude mixture comprising 5-formylvalerate compound and 2-, 3- and/or 4-formylvalerate compound by vacuum distillation, wherein the distillation is per...
|
|
WO/2000/047563A1 |
Lactam inhibitors are provided which have structure (I) wherein X is (2) or (3), Y is O or S and R?4¿ is (4), R?7¿O- or R?8¿, and R?1¿, R?2¿, R?3¿, R?5¿, R?6¿, R?7¿, and R?8¿, are as defined herein. These compounds are inhibito...
|
|
WO/2000/047207A1 |
Caprolactam inhibitors are provided which have structure (I) including pharmaceutically acceptable salts thereof and all stereoisomers thereof, and prodrugs thereof, wherein n is 1 to 5; and Y, R?1¿, R?2¿, R?3¿, R?5¿, R?5a¿, R?6¿, ...
|
